Previous Close | 2.4000 |
Open | 2.3915 |
Bid | 2.0300 x 1100 |
Ask | 2.9000 x 800 |
Day's Range | 2.3100 - 2.4300 |
52 Week Range | 2.2300 - 4.1500 |
Volume | |
Avg. Volume | 59,831 |
Market Cap | 115.363M |
Beta (5Y Monthly) | 0.78 |
PE Ratio (TTM) | 23.80 |
EPS (TTM) | 0.1000 |
Earnings Date | Mar 14, 2022 - Mar 18, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Spare a thought for those who held...
Approval adds HPV to menu of tests available on Enzo’s GenFlex® platform, which includes COVID-19 PCR and CT/NG/TVNEW YORK, NY, April 19, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced that it has received approval from the New York State Department of Health (DOH) for its AMPIPROBE® HPV test. The AMPIPROBE® HPV test is Enzo’s PCR-based test designed to detect 14 high-risk human papillomavirus (HPV) vari
FOR IMMEDIATE RELEASE All Four Proposals Approved NEW YORK, NY, April 12, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced the approval of all proposals presented at its most recent Annual Meeting of Shareholders. “Approval of these proposals improves our corporate governance and allows our refreshed leadership team to further prioritize shareholder-friendly initiatives,” stated Hamid Erfanian, Chief Execu